Altimmune ALT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $26K+420% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $16.19M-12.0% | $18.41M+23.1% | $14.96M-13.2% | $17.24M+8.9% | $15.83M-20.0% | ||
| $8.05M-23.4% | $10.51M+78.0% | $5.9M+3.7% | $5.69M-5.0% | $5.99M+17.7% | ||
| $24.24M-16.2% | $28.92M+38.6% | $20.86M-9.0% | $22.93M+5.1% | $21.82M-12.3% | ||
| $24.24M-16.2% | $28.92M+38.6% | $20.86M-9.0% | $22.93M+5.1% | $21.82M-12.3% | ||
| -$24.24M+16.1% | -$28.89M-38.5% | -$20.86M+9.0% | -$22.92M-5.1% | -$21.82M+12.3% | ||
| $1.07M+21.9% | $876K+77.0% | $495K+87.5% | $264K+26,300% | $1K0.0% | ||
| $2.9M+19.0% | $2.44M+0.5% | $2.43M+114% | $1.13M-26.7% | $1.55M-1.5% | ||
| $1.68M+9.5% | $1.54M-16.8% | $1.85M+138% | $776K-50.2% | $1.56M-7.5% | ||
| -$22.56M+17.5% | -$27.36M-43.9% | -$19.01M+14.1% | -$22.15M-9.3% | -$20.26M+12.6% | ||
| —— | —— | —— | —— | -$681K— | ||
| -$22.56M+17.5% | -$27.36M-43.9% | -$19.01M+14.1% | -$22.15M-13.1% | -$19.58M+15.6% | ||
| -$0.18+30.8% | -$0.26-23.8% | -$0.21+22.2% | -$0.27-3.8% | -$0.26+21.2% | ||
| -$0.18+30.8% | -$0.26-23.8% | -$0.21+22.2% | -$0.27-3.8% | -$0.26+21.2% | ||
| 124.5M+41.3% | 88.1M-1.5% | 89.4M+9.7% | 81.5M+7.8% | 75.5M+6.4% | ||
| 124.5M+41.3% | 88.1M-1.5% | 89.4M+9.7% | 81.5M+7.8% | 75.5M+6.4% | ||
| $23K-11.5% | $26K-3.7% | $27K-10.0% | $30K+3.4% | $29K-12.1% | ||
| -$296K-436% | $88K+283% | $23K+164% | -$36K-20.0% | -$30K— | ||
| -$152K-463% | -$27K+68.6% | -$86K+6.5% | -$92K-713% | $15K-87.3% | ||
| -$24.24M+16.1% | -$28.89M-38.5% | -$20.86M+9.0% | -$22.92M-5.1% | -$21.82M+12.3% | ||
| -$24.22M+16.1% | -$28.87M-38.6% | -$20.83M+9.0% | -$22.89M-5.1% | -$21.79M+12.3% | ||
| -$24.22M+16.1% | -$28.87M-38.6% | -$20.83M+9.0% | -$22.89M-5.1% | -$21.79M+12.3% | ||
| -$24.24M+16.1% | -$28.89M-38.5% | -$20.86M+9.0% | -$22.92M-5.1% | -$21.82M+12.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Altimmune's revenue?
- Altimmune (ALT) generated $41.0K in revenue over the trailing twelve months, up 105.0% year over year.
- Is Altimmune profitable?
- Altimmune is not currently profitable: it reported a net loss of $91.1M over the trailing twelve months, a -214861.0% net margin.
- What is Altimmune's earnings per share?
- Altimmune's diluted EPS over the trailing twelve months is $-0.92.
- Where does Altimmune's income statement data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
